A strategically important European API champion priced for failure—where FOCUS-27 execution, Sanofi volume replacement, and regulatory perfection determine whether the stock becomes a multi-bagger or stays distressed.
Overview
Euroapi is a strategically important European API manufacturer carved out of Sanofi and listed in 2022, now in the trough of a high-risk industrial turnaround. The business combines large-scale API Solutions (about 200 products, >500 customers across 80 countries) with a growing CDMO offering for complex chemistry and newer modalities. Euroapi’s ‘moat’ is structural: stringent regulatory compliance, high switching costs because APIs are locked into regulatory filings, and specialized assets in fermentation (Vitamin B12), HPAPIs (prostaglandins), and large molecules (peptides/oligonucleotides). Financially, FY2025 net sales fell to €848.2m (-7%) due largely to Sanofi destocking, but Core EBITDA rose to €66.2m (7.8% margin) on cost discipline. Reported results remain deeply loss-making (net loss €211.2m) due to impairments and tax asset write-downs. Success hinges on executing FOCUS-27, scaling higher-value CDMO projects, and divesting/rightsizing non-core assets to close a large ‘execution discount’ embedded in the current distressed valuation.